This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Biogen Past Earnings Performance
Past criteria checks 0/6
Biogen's earnings have been declining at an average annual rate of -11.2%, while the Biotechs industry saw earnings growing at 17% annually. Revenues have been declining at an average rate of 3.7% per year. Biogen's return on equity is 7.4%, and it has net margins of 13.8%.
Key information
-11.20%
Earnings growth rate
-10.35%
EPS growth rate
Biotechs Industry Growth
11.51%
Revenue growth rate
-3.75%
Return on equity
7.36%
Net Margin
13.81%
Last Earnings Update
31 Mar 2026
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Biogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
BATS-CHIXE:IDPD Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
9,937
1,372
2,469
1,777
31 Dec 25
9,891
1,293
2,434
1,729
30 Sep 25
10,066
1,609
2,427
1,372
30 Jun 25
9,997
1,531
2,412
2,340
31 Mar 25
9,816
1,479
2,381
1,902
31 Dec 24
9,676
1,632
2,387
1,905
30 Sep 24
9,608
1,615
2,314
1,967
30 Jun 24
9,672
1,159
2,489
1,304
31 Mar 24
9,663
1,167
2,476
2,326
31 Dec 23
9,836
1,161
2,502
2,442
30 Sep 23
9,993
1,462
2,532
2,490
30 Jun 23
9,972
2,665
2,343
2,303
31 Mar 23
10,105
3,131
2,379
2,248
31 Dec 22
10,173
3,047
2,409
2,229
30 Sep 22
10,363
2,865
2,570
2,325
30 Jun 22
10,634
2,059
2,661
2,478
31 Mar 22
10,820
1,450
2,726
2,535
31 Dec 21
10,982
1,556
2,680
2,497
30 Sep 21
11,101
1,546
2,700
3,522
30 Jun 21
11,698
1,918
2,619
3,960
31 Mar 21
12,604
3,012
2,536
4,023
31 Dec 20
13,445
4,001
2,516
3,985
30 Sep 20
14,263
5,082
2,370
2,949
30 Jun 20
14,487
5,927
2,351
2,348
31 Mar 20
14,422
5,879
2,365
2,178
31 Dec 19
14,378
5,889
2,359
2,273
30 Sep 19
14,233
5,396
2,285
2,193
30 Jun 19
14,072
5,294
2,229
2,160
31 Mar 19
13,812
4,667
2,176
2,664
31 Dec 18
13,453
4,431
2,109
2,597
30 Sep 18
13,234
3,187
2,070
2,573
30 Jun 18
12,872
2,968
2,007
2,512
31 Mar 18
12,594
2,964
1,921
2,327
31 Dec 17
12,274
2,539
1,936
2,254
30 Sep 17
11,839
3,486
1,859
2,200
30 Jun 17
11,717
3,293
1,887
2,283
31 Mar 17
11,533
3,480
1,949
1,959
31 Dec 16
11,449
3,703
1,950
1,973
30 Sep 16
11,416
3,885
2,035
1,981
30 Jun 16
11,238
3,818
2,051
1,972
31 Mar 16
10,936
3,695
2,050
1,990
31 Dec 15
10,764
3,547
2,113
2,013
30 Sep 15
10,565
3,599
2,104
1,971
30 Jun 15
10,299
3,490
2,196
1,869
Quality Earnings: IDPD has a large one-off loss of $966.3M impacting its last 12 months of financial results to 31st March, 2026.
Growing Profit Margin: IDPD's current net profit margins (13.8%) are lower than last year (15.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IDPD's earnings have declined by 11.2% per year over the past 5 years.
Accelerating Growth: IDPD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IDPD had negative earnings growth (-7.3%) over the past year, making it difficult to compare to the Biotechs industry average (7.2%).
Return on Equity
High ROE: IDPD's Return on Equity (7.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/02 13:44
End of Day Share Price
2026/05/22 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biogen Inc. is covered by 58 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.